Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) shares passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.36 and traded as low as $2.36. Oramed Pharmaceuticals shares last traded at $2.37, with a volume of 43,141 shares trading hands.
Analyst Ratings Changes
Separately, StockNews.com downgraded shares of Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Wednesday, February 19th.
Check Out Our Latest Analysis on ORMP
Oramed Pharmaceuticals Stock Down 0.6 %
The company has a market cap of $94.93 million, a P/E ratio of 21.41 and a beta of 1.61. The stock has a 50 day moving average price of $2.30 and a two-hundred day moving average price of $2.36.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Oramed Pharmaceuticals during the third quarter worth $272,000. Murchinson Ltd. raised its stake in Oramed Pharmaceuticals by 0.5% in the 3rd quarter. Murchinson Ltd. now owns 1,708,879 shares of the biotechnology company's stock worth $4,170,000 after purchasing an additional 8,889 shares in the last quarter. XTX Topco Ltd raised its stake in Oramed Pharmaceuticals by 59.7% in the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company's stock worth $60,000 after purchasing an additional 9,242 shares in the last quarter. Marquette Asset Management LLC bought a new stake in Oramed Pharmaceuticals in the 4th quarter valued at about $81,000. Finally, Peapod Lane Capital LLC acquired a new position in shares of Oramed Pharmaceuticals during the 4th quarter worth approximately $550,000. 12.73% of the stock is owned by institutional investors and hedge funds.
Oramed Pharmaceuticals Company Profile
(
Get Free Report)
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
See Also
Before you consider Oramed Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.
While Oramed Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
